

Cystadenocarcinoma Serous

[View the current Cystadenocarcinoma Serous InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Cystadenocarcinoma_Serous.html) - Regularly Updated.

Recent Publications on Cystadenocarcinoma Serous:



- [Ovarian cancer update: lessons from morphology, molecules, and mice.](#)
*Ovarian carcinomas are a heterogeneous group of neoplasms. Pathologists...*18th November, 2009
Department of Pathology, University of Michigan Health System, Ann Arbor,- Arch Pathol Lab Med. 2009 Nov;133(11):1775-81.
- [Cutaneous metastasis of uterine papillary serous carcinoma presenting as a solitary nodule on the umbilical area.](#)
*Clinical management of pelvic relapses from gynecologic malignancies...*13th November, 2009
- Acta Derm Venereol. 2009;89(5):544-5. ([DOI Direct Link](#))
- [Stereotactic body radiosurgery for pelvic relapse of gynecologic malignancies.](#)
*Clinical management of pelvic relapses from gynecologic malignancies...*11th November, 2009
Department of Radiation Oncology, Hospital of Cleveland MAILSTOP: LTR 6068- Technol Cancer Res Treat. 2009 Oct;8(5):393-400.
- [Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.](#)
*Neoadjuvant chemotherapy followed by interval debulking has become an...*10th November, 2009
Department of Pathology, Singapore General Hospital, Singapore.- Int J Gynecol Pathol. 2009 Sep;28(5):442-6. ([DOI Direct Link](#))
- [Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.](#)
*Our previous study has suggested that the cell cycle-related kinase (CCRK)...*7th November, 2009
State Key Laboratory of Oncology in South China, Cancer Center, Sun- Int J Cancer. 2009 Dec 1;125(11):2631-42. ([DOI Direct Link](#))
- [Uterine papillary serous carcinoma: patterns of failure and survival.](#)
*OBJECTIVE: To evaluate the outcome in patients with uterine papillary...*5th November, 2009
Department of Radiation Oncology, Westmead Hospital, Sydney, New South- Aust N Z J Obstet Gynaecol. 2009 Aug;49(4):419-25. ([DOI Direct Link](#))
- [Secondary cytoreduction in epithelial ovarian cancer recurrence: a perspective from a regional cancer center in India.](#)
*OBJECTIVE: To assess the impact of secondary cytoreduction on survival in...*29th October, 2009
Division of Surgical Oncology, Regional Cancer Centre, Medical College- J Reprod Med. 2009 Aug;54(8):506-10.
- [Qualitative age interactions between low-grade and high-grade serous ovarian carcinomas.](#)
*PURPOSE: Ovarian epithelial carcinomas, including the predominant serous...*21st October, 2009

Department of Pathology, F. Edward Hebert School of Medicine, Uniformed- Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2256-61. Epub 2009 Jul ([DOI Direct Link](#))

- [An updated clinicopathologic study of early-stage uterine papillary serous carcinoma \(UPSC\).](#)
*OBJECTIVES: Stage I-II uterine papillary serous carcinoma (UPSC) patients...*20th October, 2009
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,- Gynecol Oncol. 2009 Nov;115(2):244-8. Epub 2009 Aug 26. ([DOI Direct Link](#))
- [Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.](#)
*OBJECTIVE: Optimal management of early-stage uterine papillary serous...*20th October, 2009
Division of Gynecologic Oncology, Department of Surgery, Roswell Park- Gynecol Oncol. 2009 Nov;115(2):249-56. Epub 2009 Aug 18. ([DOI Direct Link](#))
- [Primary peritoneal psammocarcinoma.](#)
*PURPOSE: Ovarian epithelial carcinomas, including the predominant serous...*6th October, 2009
Specialist Registrar in Obstetrics and Gynaecology, Department of- J Obstet Gynaecol. 2009 Jul;29(5):453-4. ([DOI Direct Link](#))
- [\[Concentration of soluble ligand for receptor CD30 \(sCD30L\)--marker of apoptosis in women with ovarian tumor\]](#)
*OBJECTIVES: Impairments of apoptosis processes are the basis of...*2nd October, 2009
Katedra i Zaklad Immunologii i Serologii, Slaski Uniwersytet Medyczny w- Ginekol Pol. 2009 Jul;80(7):494-7.
- [The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.](#)
*BACKGROUND: Recent studies proposed L1CAM (L1 cell adhesion molecule)...*1st October, 2009
Institute of Pharmacogenetics, University of Duisburg-Essen, Hufelandstr.- Anticancer Res. 2009 Aug;29(8):3449-52.
- [Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.](#)
*BACKGROUND: To identify immunosuppressive elements present in ovarian...*1st October, 2009
The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical- Anticancer Res. 2009 Aug;29(8):2875-84.
- [Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis.](#)
*AIMS AND BACKGROUND: The literature data show that the most frequently...*11th September, 2009
Department of Medical Genetics, Medical University, Sofia, Bulgaria.- Tumori. 2009 May-Jun;95(3):357-66.

BioNews Results for Cystadenocarcinoma Serous

- [Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial](#)
MDLinx: Nov 9 2009 11:51AM Matching: serous
- [Optical Coherence Tomography Features of Acute Central Serous Chorioretinopathy versus Neovascular Age-Related Macular Degeneration](#)
British Journal of Ophthalmology: Oct 14 2009 11:28PM Matching: serous
- [Optical Coherence Tomography Features of Acute Central Serous Chorioretinopathy versus Neovascular Age-Related Macular Degeneration \[Clinical Science\]](#)
British Journal of Ophthalmology: Oct 13 2009 4:09AM Matching: serous

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

